Little D, Nee R, Abbott K, et al. Cost utility analysis of sodium polystyrene sulfate vs. potential alternatives for chronic hyperkalemia. Clinical Nephrology, 2014; 81: 259-268

Clinical Nephrology

Volumn 83, Issue 6, 2015, Pages 380-381

  Straube, Barry ^a   Reaven, Nancy ^b   Funk, Susan ^b  

^a Marwood Group   (United States)

^b Strategic Health Resources   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAXATIVE; PLACEBO; POLYSTYRENE; SODIUM DERIVATIVE; SODIUM POLYSTYRENE SULFATE; SORBITOL; SULFATE; UNCLASSIFIED DRUG; CATION EXCHANGE RESIN; POLYSTYRENE DERIVATIVE;

ANOREXIA; CHRONIC HYPERKALEMIA; CLINICAL PRACTICE; COLON DISEASE; COLON NECROSIS; CONSTIPATION; COST UTILITY ANALYSIS; DIARRHEA; DRUG COST; DRUG SAFETY; ELECTROLYTE DISTURBANCE; ELECTRONIC MEDICAL RECORD; HUMAN; HYPERKALEMIA; HYPERVOLEMIA; INTESTINE NECROSIS; INTESTINE OBSTRUCTION; ISCHEMIC COLITIS; LETTER; LONG TERM CARE; NAUSEA; OUTCOME ASSESSMENT; POTASSIUM EXCRETION; PRESCRIPTION; RECTUM HEMORRHAGE; STOMACH IRRITATION; VOMITING; ECONOMICS; FEMALE; MALE;

CATION EXCHANGE RESINS; FEMALE; HUMANS; HYPERKALEMIA; MALE; POLYSTYRENES;

EID: 84938087950     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108507A     Document Type: Letter

References (9)

1. Little DJ, Nee R, Abbott KC, Watson MA, Yuan CM. Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia. Clin Nephrol. 2014; 81: 259-268. CrossRef PubMed
2. Chernin G, Gal-Oz A, Ben-Assa E, Schwartz IF, Weinstein T, Schwartz D, Silverberg DS. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy. Clin Cardiol. 2012; 35: 32-36. CrossRef PubMed
3. Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998; 9: 1535-1543. PubMed
4. Khanna A, White WB. The management of hyperkalemia in patients with cardiovascular disease. Am J Med. 2009; 122: 215-221. CrossRef PubMed
5. Emmett M, Hootkins RE, Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology. 1995; 108: 752-760. CrossRef PubMed
6. Watson MA, Baker TP, Nguyen A, Sebastianelli ME, Stewart HL, Oliver DK, Abbott KC, Yuan CM. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis. 2012; 60: 409-416. CrossRef PubMed
7. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ; PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011; 32: 820-828. CrossRef PubMed
8. Weir M, Bakris G, Bushinsky D, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015; 372: 211-221. PubMed
9. Kayexalate Package Insert. http://www.accessdata. fda.gov/drugsatfda_docs/la bel/2009/011287s021lbl.pdf; accessed September 8, 2014.